Scholar Rock Holding (SRRK) Non-Current Assets (2017 - 2026)
Scholar Rock Holding's quarterly Non-Current Assets came in at $20.0 million in Q1 2026, down 10.47% year-on-year from $22.3 million in Q1 2025, and up 4.42% quarter-over-quarter from $19.1 million in Q4 2025.
Scholar Rock Holding has reported Non-Current Assets for 10 years, with the latest figure at $20.0 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 10.47% year-over-year to $20.0 million; the trailing twelve-month figure through Mar 2026 stood at $81.0 million (down 18.98% YoY), and the FY2025 full-year result was $19.1 million, down 19.5% from the prior year.
- Non-Current Assets for Q1 2026 stood at $20.0 million, up from $19.1 million in the prior quarter.
- The five-year high for Non-Current Assets was $37.4 million in Q1 2022, with the low at $19.1 million in Q4 2025.
- Average Non-Current Assets over 5 years is $25.5 million, with a median of $23.8 million recorded in 2024.
- Year-over-year, Non-Current Assets slumped 32.02% in 2023 and increased 17.92% in 2024.
- Tracing SRRK's Non-Current Assets over 5 years: stood at $30.1 million in 2022, then fell by 24.23% to $22.8 million in 2023, then gained by 4.01% to $23.8 million in 2024, then dropped by 19.5% to $19.1 million in 2025, then advanced by 4.42% to $20.0 million in 2026.
- The last three Non-Current Assets figures came in at $20.0 million (Q1 2026), $19.1 million (Q4 2025), and $21.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 19.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.97 Mn |
| Dec 31, 2025 | 19.13 Mn |
| Sep 30, 2025 | 21.01 Mn |
| Jun 30, 2025 | 20.92 Mn |
| Mar 31, 2025 | 22.31 Mn |
| Dec 31, 2024 | 23.76 Mn |
| Sep 30, 2024 | 26.21 Mn |
| Jun 30, 2024 | 27.73 Mn |
| Mar 31, 2024 | 20.35 Mn |
| Dec 31, 2023 | 22.84 Mn |
| Sep 30, 2023 | 22.22 Mn |
| Jun 30, 2023 | 25.09 Mn |
| Mar 31, 2023 | 27.56 Mn |
| Dec 31, 2022 | 30.14 Mn |
| Sep 30, 2022 | 32.69 Mn |
| Jun 30, 2022 | 34.99 Mn |
| Mar 31, 2022 | 37.39 Mn |
| Dec 31, 2021 | 39.13 Mn |
| Sep 30, 2021 | 40.23 Mn |
| Jun 30, 2021 | 41.69 Mn |
| Mar 31, 2021 | 42.09 Mn |
| Dec 31, 2020 | 43.90 Mn |
| Sep 30, 2020 | 44.04 Mn |
| Jun 30, 2020 | 11.17 Mn |
| Mar 31, 2020 | 11.53 Mn |
| Dec 31, 2019 | 11.21 Mn |
| Sep 30, 2019 | 9.30 Mn |
| Jun 30, 2019 | 8.53 Mn |
| Mar 31, 2019 | 8.95 Mn |
| Dec 31, 2018 | 3.40 Mn |
| Sep 30, 2018 | 2.83 Mn |
| Jun 30, 2018 | 2.06 Mn |
| Dec 31, 2017 | 2.44 Mn |